THUDIUM; Kent B.

Patent Applications and Registrations

Patent applications and USPTO patent grants for THUDIUM; Kent B..The latest application filed is for "human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof".

Company Profile

10.18.23

THUDIUM; Kent B. - Oakland CA
Thudium; Kent B. - Milpitas CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof App 20220204612 - THUDIUM; Kent B. ; et al.	2022-06-30
Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof App 20220195040 - THUDIUM; Kent B. ; et al.	2022-06-23
Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof Grant 11,236,165 - Thudium , et al. February 1, 2	2022-02-01
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof Grant 11,236,164 - Thudium , et al. February 1, 2	2022-02-01
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof Grant 11,236,163 - Thudium , et al. February 1, 2	2022-02-01
Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof App 20210261661 - THUDIUM; Kent B. ; et al.	2021-08-26
Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof App 20210261660 - THUDIUM; Kent B. ; et al.	2021-08-26
Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof App 20210261662 - THUDIUM; Kent B. ; et al.	2021-08-26
Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereof Grant 11,001,630 - Thudium , et al. May 11, 2	2021-05-11
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof Grant 10,988,536 - Thudium , et al. April 27, 2	2021-04-27
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof Grant 10,988,535 - Thudium , et al. April 27, 2	2021-04-27
Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof App 20200385467 - THUDIUM; Kent B. ; et al.	2020-12-10
Human Antibodies that Bind Lymphocyte Activation Gene-3 (LAG-3), and Uses Thereof App 20200385466 - THUDIUM; Kent B. ; et al.	2020-12-10
Human Antibodies That Bind Lymphocyte Activation Gene-3 (lag-3), And Uses Thereof App 20200231671 - THUDIUM; Kent B. ; et al.	2020-07-23
Human Antibodies That Bind Lymphocyte Activation Gene-3 (lag-3), And Uses Thereof App 20190276539 - Thudium; Kent B. ; et al.	2019-09-12
Human Antibodies That Bind Lymphocyte Activation Gene-3 (lag-3), And Uses Thereof App 20190276538 - Thudium; Kent B. ; et al.	2019-09-12
Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof Grant 10,344,089 - Thudium , et al. July 9, 2	2019-07-09
Fully Human Antibodies To Btla App 20190119381 - MATARAZA; Jennifer Marie ; et al.	2019-04-25
Fully human antibodies to BTLA Grant 10,155,813 - Mataraza , et al. Dec	2018-12-18
Human Antibodies That Bind Lymphocyte Activation Gene-3 (lag-3), And Uses Thereof App 20180066054 - THUDIUM; Kent B. ; et al.	2018-03-08
Fully Human Antibodies To Btla App 20160222114 - MATARAZA; Jennifer Marie ; et al.	2016-08-04
Fully human antibodies to BTLA Grant 9,346,882 - Mataraza , et al. May 24, 2	2016-05-24
Fully Human Antibodies To Btla App 20140017255 - MATARAZA; Jennifer Marie ; et al.	2014-01-16
Fully human antibodies to BTLA Grant 8,563,694 - Mataraza , et al. October 22, 2	2013-10-22
Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof Grant 8,263,073 - Korman , et al. September 11, 2	2012-09-11
Fully Human Antibodies To Btla App 20120183565 - Mataraza; Jennifer Marie ; et al.	2012-07-19
Cytomegalovirus Intron A Fragments App 20120100573 - THUDIUM; Kent B. ; et al.	2012-04-26
Human Antibodies That Bind Lymphocyte Activation Gene-3 (lag-3) And Uses Thereof App 20110150892 - Thudium; Kent B. ; et al.	2011-06-23
Anti-ctla-4 Antibodies With Reduced Blocking Of Binding Of Ctla-4 To B7 And Uses Thereof App 20110081354 - Korman; Alan ; et al.	2011-04-07
Cytomegalovirus Intron A fragments Grant 7,846,687 - Thudium , et al. December 7, 2	2010-12-07
Hepatitis C virus asialoglycoproteins App 20080318275 - Ralston; Robert O. ; et al.	2008-12-25
Antibodies to hepatitis C virus asialoglycoproteins Grant 7,105,303 - Ralston , et al. September 12, 2	2006-09-12
Cytomegalovirus intron a fragments App 20050191727 - Thudium, Kent B. ; et al.	2005-09-01
Cytomegalovirus Intron A fragments Grant 6,893,840 - Thudium , et al. May 17, 2	2005-05-17
Antibodies to hepatitis C virus asialoglycoproteins App 20050089843 - Ralston, Robert O. ; et al.	2005-04-28
Cytomegalovirus Intron A Fragments App 20050079488 - Thudium, Kent B. ; et al.	2005-04-14
Hepatitis C virus asialoglycoproteins App 20020004048 - Ralston, Robert O. ; et al.	2002-01-10
Hepatitis C virus asialoglycoproteins Grant 6,274,148 - Ralston , et al. August 14, 2	2001-08-14
Noncloning technique for expressing a gene of interest Grant 6,096,505 - Selby , et al. August 1, 2	2000-08-01
Hepatitis C virus asialoglycoproteins Grant 5,942,234 - Ralston , et al. August 24, 1	1999-08-24

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.